Renal prognoses by different target hemoglobin levels achieved by therapy with epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis stimulating agent: multicenter open-label randomized controlled study - RADIANCE-CKD Study

Fukuoka Renal Clinic/J-CRSU Co., Ltd.0 个研究点目标入组 500 人开始时间: 2012年8月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Anemia for other reasons than the renal anemia: Complication of apparent hemorrhagic lesion, hematologic disease (e.g. leukemia, malignant lymphoma, myelodysplastic syndrome, aplastic anemia), apparent chronic inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease), or being on myelosuppressive therapy (chemotherapy or radiotherapy) for malignant tumor (2) Iron deficiency: Serum ferritin <100 ng/mL and transferrin saturation (TSAT) <20% (3) Received renal-transplant (4) eGFR <6.0 mL/min/1.73 m2 (5) Hypersensitivity to epoetin beta pegol, erythropoietin, or darbepoetin alfa (6) Pregnancy, nursing or planning to become pregnant during the study (women only) (7) Participation in other clinical trials at enrollment (8) Judged as ineligible in the opinion of the investigator

发起方

Fukuoka Renal Clinic/J-CRSU Co., Ltd.